Adam Mortara, Scott McBride, Nevin Gewertz, Faye Paul and Taylor Meehan win ANDA trial for Bayer and Endo Pharmaceuticals
Adam Mortara, Scott McBride, Nevin Gewertz, Faye Paul and Taylor Meehan won a complete trial victory for Bayer and Endo Pharmaceuticals in ANDA litigation over Endo’s testosterone undecanoate intramuscular injection Aveed®. Aveed® is the first FDA-approved long-acting testosterone replacement therapy injectable. Defendant Custopharm, Inc. sought to market a generic version of Aveed® and challenged as obvious two patents covering Aveed®’s unique composition and dosing regimen. After a bench trial, Judge Sue Robinson of the District of Delaware issued a memorandum opinion and order finding that Custopharm, Inc. had failed to show that the patents covering Aveed® were invalid as obvious.
Read the full opinion here.